US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
pharma · Birch Pollen-induced Allergic Rhinoconjunctivitis
Allergon AB
Allergen
Allergon AB drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SE HQ
23 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- SE
- Employees
- 23
- Programs
- 1
- Drugs
- 6
- Patents
- 24
Allergon AB pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Allergon AB drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Allergon AB in public FDA and regional records.
-
Development asset linked to Allergon AB in public FDA and regional records.
-
Development asset linked to Allergon AB in public FDA and regional records.
-
Development asset linked to Allergon AB in public FDA and regional records.
-
Development asset linked to Allergon AB in public FDA and regional records.